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Abstract
Objective: To review the existing literature on histamine and migraine with a focus on the molecule, its receptors,
its use in inducing migraine, and antihistamines in the treatment of migraine.
Background: Histamine has been known to cause a vascular type headache for almost a hundred years. Research
has focused on antihistamines as a possible treatment and histamine as a migraine provoking agent but there has
been little interest in this field for the last 25 years. In recent years two additional histamine (H3 and H4) receptors
have been discovered and a series of non-sedating antihistamines have been developed. It is therefore timely to
review the field again.
Methods: For this review the PubMed/MEDLINE database was searched for eligible studies. We searched carefully
for all articles on histamine, antihistamines and histamine receptors in relation to migraine and the nervous system.
The following search terms were used: histamine, migraine disorders, migraine, headache, antihistamines, histamine
antagonists, clinical trials, induced headache, histamine H3 receptor, histamine H4 receptor and pharmacology. Four
hundred thirty-six titles were read, 135 abstracts were read, 112 articles were read in full and 53 articles were used
in this review. Review process resulted in 12 articles added to a total of 65.
Findings: Early studies of H1 and H2 antihistamines lack scientific strength and show conflicting results. Most of the
antihistaminic drugs used in these trials bind also to other receptors which makes it difficult to conclude on the
antihistaminic effect. Histamine is an efficient inducer of migraine attacks in migraine patients by an H1 mechanism
most likely extracerebrally. These findings merit further investigation of antihistamines in clinical drug trials. The H3
and H4 receptors are found in primarily in CNS and immune tissues, respectively. H3 is likely to be involved in
antinociception and has been linked with cognitive, neurodegenerative and sleep disorders. The only marketed H3
agent, pitolisant, is a brain penetrant H3 antagonist/inverse agonist which increases central histamine and causes
headache. The experimental H3 agonist N
α-methylhistamine has shown promising results as a migraine
preventative in studies of uncertain quality. With the current limited knowledge of the H4 receptor it is
questionable whether or not the receptor is involved in migraine.
Conclusion: There is insufficient support for first generation antihistamines (both H1 and H2) as preventive migraine
medications and sedation and weight gain are unacceptable side effects. Non-sedating H1 antihistamines need to
be appropriately tested. Central H3 receptors seem to have a role in migraine that merit further investigation. The
histaminergic system may be a goal for novel migraine drugs.
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Introduction
Histamine is a biogenic monoamine synthesized from the
amino acid L-histidine by the L-histidine decarboxylase and
metabolized by the enzyme histamine N-methyltransferase,
using S-adenosylmethionine as a methyl donor. Histamine
is located throughout the entire organism with high
concentrations in lungs, skin and gastrointestinal tract.
It is synthesized and stored in mast cells and basophils.
It plays a role in multiple mechanisms both immuno-
logical and physiological, stimulating gastric secretion,
inflammation, smooth muscle contraction, vasodi-
latation, permeability and much more. Histamine also
functions as a neurotransmitter. It is synthesized in
histaminergic neurons located in the posterior hypothal-
amus. These neurons have axons extending throughout
the brain. Histamine carries out its effects via 4 subtypes
of 7-transmembrane G-protein coupled receptors; H1, H2,
H3 and H4 receptors [1–3].
The relation between histamine and headache has
been on the agenda for almost a hundred years. A multi-
tude of studies have been published focusing on the
ability of histamine to induce headache and on the effect
of antihistamines in the treatment of headache. During
the last two decades the issue has, however, received
almost no interest apart from two reviews [2, 4]. One
reason that we now take this issue up is that there has
been a massive development in the basic understanding
of histamine biology, including the growing knowledge
of histamine H3 and H4 receptors. Another is that a
series of new generation antihistaminic drugs with or
without the ability to penetrate the blood brain barrier
have become available. It is therefore timely to review
the issue.
Methods
Literature used in this review was primarily searched in
the PubMed/MEDLINE database and we limited our
search to publications in English. References were
selected by reading titles and abstracts judging relevance
to the topic. We began our search with a screening to
identify existing reviews of histamine and migraine. The
search histamine [MeSH Terms] OR histamine [All
Fields]) AND migraine disorders [MeSH Terms] OR
migraine [All Fields] AND disorders [All Fields] OR
migraine disorders [All Fields] OR migraine [All Fields]
with only articles from the last 5 years resulted in 41
articles of which 9 abstracts were read. We then searched
for the very early literature of histamine and vascular
headaches. This literature dates back almost a century and
a systematic search is not possible. Therefore, bibliography
from the PhD thesis by Lassen LH was examined to
obtain references. Six articles were found eligible. To
find articles regarding the studies of histamine antago-
nists in migraine prophylaxis we searched for the terms:
antihistamine AND (migraine OR headache) AND clin-
ical trial from 1945 to 1985. This resulted in 68 articles
of which 41 abstracts were read. Articles concerning
migraine provocation studies with histamine were
searched for using the terms: histamine AND induced
AND headache from 1980 to present. One hundred
twenty-three articles were found of which 24 abstracts
were read. Articles of histamine H3 and H4 receptor
pharmacology was searched for by the MeSH terms:
Pharmacology AND Receptors, histamine with review
as publication type. The search lead to 44 articles of
which 21 abstracts were read. Individual free text
searches of histamine H3 receptor OR histamine H4
receptor AND pharmacology from 2000 until present
was made and yielded 160 articles of which 40 abstracts
were read. In addition to the search results we looked
through the reference lists of the selected articles to find
more relevant studies. The search combined resulted in
436 titles, of which 135 abstracts were read and 112
articles were read in full. Fifty-three were included in this
review. Review process resulted in 12 articles added to a
total of 65.
Historical overview
The research of histamine began over a century ago [5],
with the first antihistamines being introduced to clinical
use around 70 years ago (Fig. 1) [1]. In 1926 Harmer and
Harris were the first to describe headache after infusion
of histamine [6]. In the 1930s Pickering did a series of
careful experimental studies. Although none of them
were placebo controlled, histamine was intelligently
investigated for its ability to induce a vascular headache.
The headache after infusion of histamine was thoroughly
described and it was shown that histamine induced
headache in a dose-dependent manner but that there
was great variability between subjects. Pickering pro-
posed that the origin of the headache was intracranial.
He suggested stretching of large intracranial arteries to be
a possible explanation of the perceived pain because head-
ache severity was reduced by lowering blood pressure or
raising intracranial pressure (i.e. less expansion of the
vasculature). He concluded that it is in the dura mater, via
its trigeminal nerve supply, that the headache arises [7].
In the following years several papers investigated the
origin of histamine induced headache. Northfield injected
histamine in the external and internal carotid artery and
concluded that the pain arose from the internal carotid
artery i.e. not from dura mater [8]. Another paper argued
that the origin of pain in migraine headache is different
from that of a histamine induced headache because of the
absence of relief of migraine headache by increasing intra-
cranial pressure while confirming a decrease of histamine
induced headache [9]. Von Storch investigated the mini-
mum dose of histamine required to induce headache.
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Migraineurs seemed to be more susceptible to histamine
induced headache than control subjects [10]. Histamine
was also tested as a treatment of migraine [11, 12]. The
idea was to induce histamine tolerance in migraineurs
based on a theory that these patients had lowered toler-
ance thus susceptible to external triggers of histamine (i.e.
foods, antigens etc.). A method found successful but
difficult to practice. The older literature had thus shown
beyond doubt that histamine could induce a vascular type
headache, the characteristics of which were carefully
described. But how close was it to migraine? This could
not be determined because there were no internationally
accepted diagnostic criteria for migraine.
Experimental in vitro and animal studies have been
performed adjacent to the clinical studies investigating
histamines vasodilatory effect in the meningeal blood
vessels as part of the underlying mechanism of migraine
[13]. The research began decades ago with multiple
studies published around the millennium [14] and
researchers continue to investigate the endogenous
mediators including histamine for their ability to gener-
ate migraine pain [15]. Histamine has been extensively
studied alongside cytokines, chemokines and vasoactive
peptides (i.e. the inflammatory soup) to gain knowledge
of the underlying cellular mechanisms producing and
maintaining the pain of migraine. At present a link
between migraine and neurogenic inflammation com-
prising mast cell degranulation is widely accepted and
this has been reviewed extensively most recently by
Ramachandran [16].
Are H1 and H2 blockers effective in migraine treatment?
Because histamine induces a vascular headache with
similarity to migraine, it was logical to test antihista-
mines in the treatment of migraine when the class of
antihistamines became available. These old drugs were
sedative and soon became classified as histamine recep-
tor 1 and 2 antagonists as no other histamine receptors
or antagonists were known at the time. The literature on
clinical trials of the H1 and H2 receptor antagonists in
the prevention of migraine is rather scarce. Few papers
have been published. Even fewer are randomized con-
trolled trials and mostly used drugs that did not bind
exclusively to H1 or H2 receptors. The following section
examines the existing literature on antihistamine trials
performed in the years from around 1960 to 2014 (see
Table 1 for overview). All the existing literature describes
antihistamines as histamine receptor antagonists. Today
most of these drugs are defined pharmacologically as
inverse agonists i.e. inhibitors of the basal receptor
activity instead of being neutral antagonists which
Fig. 1 Historical timeline of histamine and its receptors. Reprinted from (11) Copyright© 2011 with permission from Elsevier, J Allergy
Clin Immunol
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solely block the agonist response [3, 17]. For ease, we
will describe all antihistamines as compounds with a
histamine antagonistic effect.
In a placebo controlled, but not double blinded or
randomized study, Curran and Lance investigated cypro-
heptadine, an antiserotonin agent with H1 receptor an-
tagonism, methysergide, a serotonin antagonist and
bellergal (mixture of phenobarbitone 20mg, ergotamine
tartrate 0.3 mg and belladonna alkaloids 0.1 mg). Their
ability to reduce attack frequency was compared and
clinical improvement was defined as either headache free
or substantially improved. Ninety-two patients received
12–24mg/day of cyproheptadine, 137 patients received
6 mg/day of methysergide, 174 patients received the
Table 1 Antihistamines in migraine prophylaxis
Type (Ligand) Participants Daily dose Duration Main findings First
author
(year)
H1 antagonist (cyproheptadine) vs. 5HT
antagonist (methysergide) vs. Bellergalb
vs. placebo
453a 12–24mg
6mg NA NA
6months Clinical improvement (Headache free or substantial
improvement)c: methysergide 64%, cyproheptadine 46%,
Bellergal 34%, placebo 20%.
Curran
(1964) (12)
Antihistaminic drug (pizotifen) 32a 1.5–2 mg NA Cessation or attenuation of attacks in 33%. Significant
reduction in migraine days and increased response to
acute medication in 40%. Increased resilience against
induced attacks. AEd: weight gain and drowsiness.
Sicuteri
(1967) (13)
Antihistaminic drug (pizotifen) 11 MAe
27 MOf
2 Cluster
headache
1.5 mg
(1–3 mg)
2–6 mo:
16
> 6 mo:
17
Significant (42.5%) clinical improvement compared to
previous placebo reports (Curran 1964).
Selby
(1970) (14)
H1 antagonist (cyproheptadine) vs.
antihistaminic drug (pizotifen) vs.
antihistaminic drug (methdilazine)
165a 12–24mg
4.5–9 mg
16–32mg
4 weeks Clinical improvement: pizotifen 58%, methdilazine 41%,
cyproheptadine 40% No placebo control.
Lance
(1970) (15)
Antihistaminic drug (pizotifen) vs. 5HT
antagonist (divascan) vs placebo
4 MAe
26 MOf
3 mg
15mg
8 weeks Significant lowered attack rate with pizotifen.
AEd: weight gain and drowsiness.
Osterman
(1977) (16)
Antihistaminic drug (pizotifen) vs
placebo
28a 3 mg 12weeks Complete resolution in 6 cases, reduced frequency and
severity in 6 and no improvement in 2 cases. No
improvement in the placebo group. AEd: weight gain
and dizziness.
Lawrence
(1977) (17)
H2 (cimetidine) vs. H2 and H1 combined
(cimetidine and chlorpheniramine) vs.
placebo
24 MO
1 basilar
migraine
200mg
cimetidine
4 mg chlor
pheniramine
1 week No significant improvement over placebo with H2
antagonist alone or in combination with H1antagonist.
AEd: weight gain and drowsiness.
Anthony
(1978) (18)
H2 (cimetidine) vs. H2 and H1 combined
(cimetidine and chlorpheniramine) vs.
placebo
6 MA
28 MO
200mg
cimetidine
4 mg chlor-
pheniramine
12weeks No significant improvement over placebo with H2
antagonist alone or in combination with H1antagonist.
AEd: weight gain and drowsiness.
Nanda
(1980) (20)
H1 (cinnarizine) 11MA
e
69 MOf
75 mg 14weeks Significant reduction in migraine days and use of acute
medication. AEd: weight gain, drowsiness, mild reversible
depression and dyspepsia.
Open label. Dropout rate 3.75%.
Rossi
(2003) (22)
H1 (cinnarizine) 60
g Up to 75mg 12weeks Significant reduction in migraine days. AEd: Palpitations
and dizziness.
Open label. Dropout rate 5%.
Togha
(2006) (21)
H1 (cinnarizine) vs valproate 86 MO
f
18 MAe
50 mg
Cinnarizine
400mg
valproate
12weeks Valproate more effective than cinnarizine.
AEd: Dry mouth, fatigue and somnolens as the most
frequent. No placebo control. Dropout rate:
23% cinnarizine, 19.4% valproate.
Bostani
(2013) (23)
H1 (cinnarizine) vs placebo 68 children
(5-17y)a
50 mg or
1.5 mg/kg
(> 30 kg)
12weeks Significant better than placebo to reduce headache
frequency by at least 50% reduction. AEd: weight gain
and drowsiness.
Dropout rate: 12% cinnarizine, 5% placebo.
Ashrafi
(2014) (24)
aNo subtype stated
bMixture of phenobarbitone 20mg, ergotamine tartrate 0.3 mg and belladonna alkaloids 0.1 mg
cNot placebo corrected
dAdverse effects
eMigraine with aura
fMigraine without aura
gSubtype unknown
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bellergal mixture and 50 were treated with placebo.
Clinical improvement was 34% with bellergal, 64% with
methysergide, 46% with cyproheptadine and 20% with
placebo. No statistical analysis was made comparing
cyproheptadine with placebo [18]. Thus, the result with
cyproheptadine is only suggestive of a possible effect of
antihistamines in migraine treatment.
Sicuteri et al. treated 32 outpatients suffering from
migraine with the antihistaminic substance named BC-105,
later known as pizotifen. BC-105 also possesses a
strong antiserotonin effect. Patients were treated with a
maintenance dose of 1.5–2 mg/day (up to 4–5 mg). No
predetermined mandatory duration was mentioned and
the study was not blinded or placebo controlled. Response
to treatment was usually experienced after 10–20 days of
treatment. A third of the patients reported absence or
significant attenuation of attacks and 40% reported a
lower frequency or increased response to acute therapy
with ergotamine. Interestingly, BC-105 increased the
resilience against migraine attacks induced with trinitro-
glycerin and reserpine. Side effects were well documented
in this study, with 90% of the patients developing an
increased appetite. Patients gained 2–5 kg during the
first month of treatment. Fatigue and drowsiness was a
side effect in 70%. The drug was administered with a
starting dose of 0.5 mg twice a day (b.i.d.) increasing to
1 mg b.i.d. after 4–5 days. This was to minimize the
initial drowsiness typically experienced during the first
period of treatment [19].
Selby et al. studied BC-105 in 40 patients, 11 with
migraine with aura, 27 with migraine without aura and 2
with cluster headache. Thirty-five were treated with a
dose of 1.5 mg (3 tablets) daily. Two patients received 1
mg and three patients received 2–3 mg/day. The design
was uncontrolled without placebo. 42.5% (17 patients)
clinically improved with 2 becoming headache free and
15 with a reduction of attack frequency between 25 and
50%. This study reported fewer side effects which the
author interpreted as a result of the lesser dose [20].
Another comparative trial investigated three drugs rele-
vant to histamine. Cyproheptadine, BC-105 (pizotifen)
and methdilazine, a drug with a four times greater anti-
histaminic action than promethazine. The patients re-
cruited were not randomly allocated and furthermore
had the possibility to shift to another group after 1
month if the current treatment failed. Because of the
free movement between the groups, only data for the
first month were statistically analyzed. The placebo
group of patients was drawn from two other studies
conducted simultaneously. Clinical improvement after
1 month was defined as headache free or a reduction in
attack frequency of at least 50%. Sixty-one patients
received cyproheptadine 4–8mg three times a day (t.i.d.)
of whom 40% improved. Fifty-three patients received
1.5–3mg of BC-105 t.i.d. with 58% improving and 51
patients received methdilazine 8–16mg b.i.d. of which
41% improved. All three resulted in a lesser improvement
than methysergide, but the compound BC-105 was also
significantly better than placebo. Cyproheptadine and
methdilazine showed only a positive trend [21].
In a double-blind placebo controlled crossover study,
Osterman investigated the effect of Sandomigran® (pizoti-
fen or BC-105), and Divascan®, a serotonin antagonist in
migraine prophylaxis. Four patients with migraine with
aura and 26 patients with migraine without aura were
included. All patients experienced at least 2–3 attacks
per month and had a confirmed diagnosis based on
then accepted criteria (Ad hoc committee on classifi-
cation of headache 1962). Three patients discontinued
due to adverse events, lack of compliance or unpleasant
side effects. Twenty-seven patients were divided into
three groups with different treatment sequences of
divascan, pizotifen and placebo. Each treatment was
given for 8 weeks in a total period of 24 weeks and all
three compounds were given in gradually increasing
doses using the same amount of capsules. The dose of
pizotifen started at 0.5 mg (1 capsule) increasing to a daily
maintenance dose of 3mg (2 capsules, t.i.d.) at day 11.
Divascan started at 2.5 mg (1 capsule) increasing to a daily
maintenance dose of 15mg (2 capsules t.i.d.) at day 11.
Side effects caused some patients to discontinue the
maintenance doses of both drugs. Four patients had
only 1.5–2.5 mg/day and 2 patients 10–12.5 mg/day of
pizotifen and divascan respectively. The patients kept a
headache diary during the trial, with attack frequency,
duration and severity as well as the use of attack medi-
cation. Severity was rated using an arbitrary 3 point
scale and only data from the last 6 weeks of each
treatment were analyzed as the first 2 weeks served as
wash out period. Treatment with pizotifen gave a
significantly lower attack frequency than both placebo and
divascan. It also significantly reduced the mean headache
index. No significant difference in the duration of attacks
was observed. Consumption of ergotamines was signifi-
cantly higher in the placebo group versus pizotifen and
divascan respectively, but not when comparing pizotifen
and divascan. In overall evaluation of the treatment
divascan did significantly better than placebo but pizo-
tifen had better effect than both placebo and divascan
with 70% reporting a good or very good effect. How-
ever, when looking at the side effects the authors found
that the treatment with pizotifen resulted in signifi-
cantly more side effects. Most frequent were drowsiness
and weight gain (> 1.5 kg) [22].
A multicenter double-blind placebo controlled study
in 36 patients in general practice also investigated the
effect of pizotifen. All patients had a history of migraine
with at least 4 attacks per month. Twenty-four of the
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patients had failed previous prophylactic therapy. The
dose of pizotifen was increased gradually to a daily dose
of 1 mg three times a day at day 24 and onwards. The
treatment period was 12 weeks and each patient kept a
record of frequency and severity of migraine attacks.
Twenty-eight patients completed the trial, 14 on pizoti-
fen and 14 on placebo. No statistical analysis was made,
but 6 patients reported complete resolution, 6 reported
reduced frequency and severity and only 2 patients
did not improve clinically. All fourteen patients given
placebo failed to show any improvement [23].
Anthony and Lance performed a controlled double
blind trial of the H2 receptor antagonist cimetidine alone
or in combination with the H1 receptor antagonist chlor-
pheniramine as migraine prophylaxis. Twenty-four
patients with migraine without aura, and 1 with basilar
symptoms received 3 different treatments, each for 1
month during 3 consecutive months. The treatments
consisted of 1 month of 200 mg (2 tablets four times a
day (q.i.d.)) cimetidine and chlorpheniramine placebo
(1 capsule q.i.d.), 1 month of 200 mg (two tablets q.i.d.)
cimetidine and chlorpheniramine maleate 4 mg (1 cap-
sule q.i.d) and 1 month of cimetidine placebo (2 tablets
q.i.d.) and chlorpheniramine placebo (1 capsule q.i.d.).
Patients were randomly allocated to the treatment
sequence and kept a record of headache intensity and
frequency as well as any side effects. Nineteen patients
completed the trial and results were that neither
cimetidine in combination with chlorpheniramine nor
cimetidine alone proved better than placebo. The
authors interpreted the outcome as a result of the intra-
cellular histamine formation by decarboxylation of his-
tidine in multiple tissues, generating headache via other
pathways or mechanisms than H1 or H2 receptors [24].
Another explanation may be a short receptor residence
time at the H1 receptor by chlorpheniramine (Ki 5–30 nM)
[4]. Furthermore, by today’s standards only 1 month of
preventative medication is not sufficient to precisely
estimate results in migraine prophylaxis. A minimum
of 3months for a phase II and up to 6months for a phase
III study is recommended [25]. Nanda et al. investigated
the same drug-placebo combination for 3months in each
group over 9 months combined. Twenty-eight patients
with migraine without aura and 6 patients with migraine
with aura were included in the trial of which 22 patients
began all three periods, but only 16 completed the full
9 months. These patients were allowed to move forward
to another treatment group before the 3 months were
completed if their headache frequency intensified. The
authors failed to show a positive effect on migraine
even with a 3 months treatment period. They found the
same side effects with drowsiness related to chlorphe-
niramine and dizziness related to cimetidine [26].
These two studies were blind and placebo controlled
and so provide the best evidence. However, using a H2
receptor antagonist alone or in combination with H1
receptor antagonist showed no significant relief of
migraine when used prophylactically.
Cinnarizine, a calcium channel antagonist with H1
antihistaminic action and a drug used in Meniere’s
disease was tested in migraine prophylaxis. Two open
label trials, one with 80 participants and another with 60
tried out cinnarizine in doses up to 75mg daily in 12 and
14weeks respectively. Safety and efficacy was measured
and both studies generally consider cinnarizine well-toler-
ated in their participants. Although both groups report a
significant reduction of headache frequency the open trial
design limits the results to only a hypothetical positive
prophylactic effect of cinnarizine [27, 28]. A double blind
parallel group study investigated cinnarizine vs. sodium
valproate. One hundred four participants were random-
ized to a daily treatment with either 50mg cinnarizine (50
participants) or 400mg valproate (54 participants) for 12
weeks. Dropout rate was ~ 20% for both arms and mainly
because of side effects. Valproate proved more effective
than cinnarizine but since there was no placebo control
efficacy results may be overestimated [29].
A double blind placebo controlled parallel group study
of cinnarizine in the prophylaxis of migraine in children
was conducted by Ashrafi et al. [30]. Sixty-eight partici-
pants aged 5–17 years with migraine with and without
aura according to the 2004 IHS criteria for migraine [31]
were randomized into 2 groups after 4 weeks of washout.
The groups consisted of a treatment group with 50 mg
cinnarizine daily (1.5 mg/kg/day for children weighing
less than 30 kg) and a placebo group. During a 12 week
treatment period participants kept a headache diary and
primary outcome measures were frequency, intensity
and duration of migraine. Adverse events were too
recorded with weight gain and extra pyramidal signs mon-
itored during the trial. Dropout rate was ~ 12% and ~ 5%
for the treatment and placebo group, respectively. Cinna-
rizine significantly reduced headache frequency to < 50%
in 60% of the patients compared to only 31.3% in the
placebo group.
In conclusion, low level of evidence and conflicting
results make it difficult to determine whether or not H1
or H2 receptor antagonists are effective in migraine
treatment. There is a reasonable indication that pizotifen,
cinnarizine and also amitriptyline have effect but they
have many other effects in addition to being antihista-
mines. More pure antihistamines such as chlorpheni-
ramine have not shown convincing efficacy. It would be
interesting to study the efficacy of pure antihistamines
using modern principles of drug trials [25]. The antihista-
mines used in the trials have primarily an H1 antagonistic
effect, but also exert antagonism on other receptors,
mainly serotonin receptors. The serotonergic effects in
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migraine is well described elsewhere [32]. Although the
complete sites of action remains to be fully described.
Serotonin and histamine are both secreted from the mast
cells in dura mater [13, 33] and it is likely that the anti-
serotonin and antihistamine effects potentiate each other,
making the results difficult to interpret. Finally the old
antihistamines could not be used in high doses because of
sedation and weight gain. It might be worth to try high
doses of non-sedating modern antihistamines.
Histamine induction of migraine
The advent of diagnostic criteria for migraine, first
unofficial [34] and then internationally accepted ICHD-1
[35] made it possible to further study the relation
between histamine induced headache and migraine.
Although histamine induction of headache dates back to
the 1920s [6] much remained to be elucidated when the
modern provocation studies began. The initial hypo-
thesis was that H1 and – to a lesser extend – H2 receptors
on intracranial blood vessels was involved, but the clinical
studies [36], experimental studies on cerebral blood flow
in human [37] and isolated intra- and extracranial blood
vessels [38] found that it was in fact the vasodilatation of
the extracerebral vessels that caused the pain.
Krabbe and Olesen investigated a 30 min intravenous
infusion of histamine with increasing doses (0.16–
0.33-0.66 μg/kg/min.) in 48 participants, 13 healthy
volunteers, 10 patients with chronic tension type headache
then called chronic muscle contraction headache and 25
patients with migraine without aura, then called common
migraine. The objective was to evaluate the sensitivity to
histamine in normal subjects and in patients with these
headaches and to develop an experimental model of vas-
cular headache. All 48 participants received a continuous
infusion of histamine chloride for 30 min. 24 of 25
migraineurs developed a throbbing headache, while
participants from the two other groups only experi-
enced, at worst, a moderate, pressing type of headache.
Adverse events from the histamine infusion consisted
mainly of a heating sensation in the face and palpi-
tations. Objectively, all participants developed a flushing
of the face, lowering of blood pressure and increased heart
rate. No serious adverse events occurred during the study.
In 18 patients who developed headache during the
histamine infusion, 0.5 mg/kg of the H1 receptor anta-
gonist mepyramine was administered intravenously for
the last 2min of the histamine infusion. Mepyramine
greatly reduced or abolished the headache in 15 of 18
migraineurs. In 10 of the patients suffering from migraine
who developed a severe throbbing headache, another
single blinded crossover study was performed with cimeti-
dine, an H2 receptor antagonist. A pretreatment with
cimetidine was administered intravenously with a bolus of
3.3 mg/kg, followed by a continuous infusion of 1.66mg/
kg/hour for 45min finished by the infusion of histamine.
The pretreatment with cimetidine slightly but significantly
decreased the headache. The only side effect was a
metallic taste in the mouth in the majority of the patients
[36]. This study proved that histamine induces more or
stronger headache in migraine patients than in normal
individuals. H1 antagonism was effective in aborting the
headache and pretreatment with an H2 antagonism had
some effect.
In a double blind placebo-controlled cross-over study,
Lassen et al. investigated whether pretreatment with the
H1 receptor antagonist mepyramine had an effect on
histamine induced headache. In 20 patients with migraine
without aura histamine was administered intravenously as
an infusion of 0.5 μg/kg/min for 20min. Prior to this a
pretreatment with 0.5mg/kg mepyramine or placebo
(0.9% NaCl) was infused intravenously for 10min. Data
from the first 3 h were documented at the study site and
then data were recorded by the patients after discharge for
8 h. Histamine induced an immediate and a delayed head-
ache. Immediate headache was defined as the headache
occurring during the first 40min after start of infusion
and the delayed headache was defined as occurring from
40min to 12 h after start of infusion.
The study was first of its kind describing that a hista-
mine infusion can provoke a delayed genuine migraine
attack in migraineurs, as 5 of 10 patients developed an
attack fulfilling IHS criteria for migraine without aura.
Pretreatment with mepyramine prevented development
of both the immediate and the delayed headache [39].
Glyceryl trinitrate (GTN), a nitric oxide donor, is also a
potent headache inducer [40] and similar to histamine
capable of inducing an immediate headache followed
hours later by a delayed migraine-like headache. The
headache caused by both substances is biphasic in
migraine patients suggesting a shared pathway. However,
GTN induced migraine is resistant to H1 receptor block-
ade with mepyramine [41] and histamine could therefore
not be the common mediator. The question of nitric oxide
being a common mediator of histamine and GTN induced
migraine was investigated in two double-blinded and pla-
cebo controlled studies, using L-NMMA, a non-selective
nitric oxide synthase inhibitor to prevent histamine
induced headache in 9 healthy male volunteers [42] and in
12 patients with migraine without aura [43]. Although
nitric oxide synthase (NOS) inhibition is effective as a
treatment of spontaneous attacks [44, 45], both studies
showed no effect on the immediate or delayed headache
induced by histamine after pre-treatment with L-NMMA.
This underlines the need of further investigation of hista-
mine’s site of action. Because histamine is unable to cross
the blood-brain barrier and H1 receptors are present in
the endothelium of cerebral arteries, migraine attacks
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could have an origin in the walls of intracerebral arteries
and not in the brain itself [41].
Histamine inhalation was investigated by Lassen et al. in
12 patients with migraine without aura, 2 patients with
migraine with aura and 1 patient with migraine both with
and without aura. They were matched with 15 healthy
volunteers in a double blind study. All participants under-
went 2 min inhalation periods with 2-fold increase in
dose of histamine for every period. The objectives were
to evaluate whether histamine inhalation could provoke a
headache, whether it showed dose-dependency, whether
induced attacks were genuine migraine attacks and
whether attacks were induced with the same frequency in
both groups. Immediate and delayed headache were
reported in both groups with no significant difference, but
only migraineurs (6 of 15) developed a headache fulfilling
the IHS criteria for migraine without aura. Development
of migraine after inhalation had a positive predictive value
of 1.0, but the sensitivity was poor. The clinical signs and
symptoms other than headache were flushing, heat sen-
sation, palpitation, coughing, dizziness and dysphonia,
none of which were severe [46].
Histamine plasma levels in migraine patients have
been reported elevated compared with controls both
ictally and interictally [47] while another study reported
no change during attacks but significant difference
between migraineurs and controls between attacks [48].
Latest unpublished results from a biomarker study in
patients with migraine without aura using mass spec-
trometry found that histamine levels both during and
outside of attacks were below detection limit and we will
not review this further.
H3 and H4 receptor pharmacology and possible
involvement in migraine
A third member of the histamine receptor family was dis-
covered pharmacologically by Arrang in 1983 when he
showed that histamine inhibited its own release from
depolarized slices of rat cerebral cortex. The receptor
responsible was identified as a presynaptic inhibitory
receptor – an autoreceptor – independent of other neuro-
transmitter antagonists and with a different ligand profile.
He concluded that a novel class of histamine receptors
was discovered and proposed the name H3 [49]. The his-
tamine H3 receptor cDNA was cloned by Lovenberg and
colleagues in 1999 and they described an extensive expres-
sion in the rat CNS especially in the caudate nucleus,
thalamus and cortex [50]. Apart from the receptor’s full
length polypeptide approximately 20 human isoforms
have been described [3]. Studies of rat, guinea pig and
human brains contribute to the knowledge of the H3
receptor’s expression in mammalian CNS. The H3 recep-
tor has been mapped by various methods such as auto-
radiography and later by in situ hybridization and reverse
transcription polymerase chain reaction of H3 receptor
mRNA. Countless studies report expression of the H3
receptor in the brain of rodents, guinea pigs, monkeys and
humans. Thus there is good evidence that histamine H3
receptor is present in many important brain structures
e.g. cortex, cerebellum, dorsal thalamus, hypothalamus,
amygdala, hippocampus, striatum and basal ganglia.
The receptor is primarily located as a presynaptic auto-
receptor on histaminergic neurons (on dendrites, axons and
somata), which are localized in the tuberomamillary nucleus
in the posterior hypothalamus of rodents and humans, or as
a heteroreceptor in non-histaminergic neurons. There is
some evidence for a postsynaptic H3 receptor in the CNS as
well as a location in the PNS (Fig. 2) [3, 51, 52].
The H3 receptor alone has been reviewed recently [52]
and alongside the H1, H2 and H4 receptors [3]. The
histamine H3 receptor has multiple signal transduction
mechanisms. The receptor couples to Gi/o protein
leading to inhibition of adenylate cyclase (AC) and a
reduction of cytosolic cAMP (the opposite action of
the H2 receptor which stimulates AC) is one of the
main signaling mechanisms (Fig. 3). The H3 receptor
also signals by activation of mitogen-activated protein
kinase (MAPK), by the Akt/PKB signaling pathway and
via activation of phospholipase C (PLC) leading to an
increase in cytosolic calcium with the latter leading to
an inhibition of histamine synthesis and release, hence
the auto-receptor function [3].
The numerous functions of the histamine H3 receptor
reflect its widespread localization in the central and peri-
pheral nervous systems as well as interactions with - and
Fig. 2 Neuronal H3 receptors are located on both histaminergic
(brown) and non-histaminergic neurons (arrows). On histaminergic
neurons H3 acts as an autoreceptor inhibiting the release of
histamine itself. The figure shows the complex distribution of H3
receptors that emphasizes the challenge of predicting the effects
mediated by H3 receptors. Reprinted from (12) Copyright© 2015
with permission from ASPET, Pharmacol Rev.
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influence by - other neurotransmitters and neuropeptides.
Many functions are still hypothetical or controversial,
particularly the effects in vivo. In general, the receptor
mediates the function of histamine itself in the nervous
system. The autoreceptor inhibits the release of histamine
from histaminergic neurons and this receptor has a sig-
nificant constitutive activity which refers to the ability of
signaling independent of agonist action. The presynaptically
located H3 receptor regulates the release of histamine and
other neurotransmitters (serotonin, GABA, glutamate,
noradrenaline and possibly acetylcholine and dopamine)
and neuropeptides in the CNS and PNS (Fig. 4). This
links the histamine H3 receptor to several neurological
and psychiatric disorders with H3 agonists being poten-
tial treatments in Alzheimer’s and Parkinson’s disease,
schizophrenia, sleep disorders and addiction [52]. H3
agonists might also perhaps be effective in migraine.
The role of histamine in neurogenic inflammation has
been reviewed by Rosa and Fantozzi who described an
interaction of mast cells and afferent nerve fibers. Mast
cell degranulation is stimulated by release of neuropep-
tides (e.g. CGRP, substance P and VIP) from the nerve
endings [16, 53] and is inhibited by histamine via the H3
receptor [54]. The degranulation of mast cells promotes
an inflammatory response including neurogenic inflam-
mation. This leads to a release of inflammatory mediators
by afferent neurons which in turn stimulate other mast
cells to degranulate and thereby sustain and prolong the
inflammation. There is evidence that mast cell de-
granulation activates meningeal nociceptors and it is
possible that mast cell degranulation has a role in migraine
[13, 33, 53, 55]. A potential therapeutic target would be a
receptor with a stabilizing function on mast cells preventing
or minimizing the degranulation and secondly the neuro-
genic inflammation. Another possible target is a receptor
located on the nerve terminals inhibiting the release of neu-
ropeptides. The H3 receptor agonist R
α-methylhistamine
inhibited plasma protein extravasation following capsaicin
or electrical stimulation of the trigeminal nerve [56]. This
suggests that neuropeptide release from sensory C fibers in
the rat meninges is at least partially controlled by H3 recep-
tors. Better knowledge of these mechanisms in neurogenic
inflammation could create a possibility of intervening with
receptor specific drugs.
Histamine reduces nociceptive transmission when
injected into the cerebrospinal fluid or microinjected in
brain structures. Central H1 and H2 receptors are
thought to mediate this effect, but theoretically H3
receptors could also be involved. An antagonist effect on
the H3 receptor leads to an increase of brain histamine
and several basic studies of acute and chronic pain tests
have investigated H3 antagonism as a modifier of noci-
ceptive thresholds. Investigation of thioperamide, an H3
receptor inverse agonist, reduces nociception in rodents,
but the effect is limited and shows a biphasic response
with decreasing effects at highest doses [57].
A single research group investigated doses of 1–10 ng
histamine injected subcutaneously twice a week as
migraine treatment [58] and subsequently compared it
with topiramate [59] in patients with refractory migraine
with positive results. Their hypothesis was that his-
tamine acts as an agonist on H3 receptors on mast cells
thereby reducing the neurogenic inflammation. The
group continued with an investigation of the H3 agonist
Nα-methylhistamine in migraine prophylaxis. They pub-
lished their results from phase I and II studies with 30
healthy volunteers and 17 patients with migraine with-
out aura and 1 patient with migraine with aura. Doses of
1–3 ng subcutaneous twice a week proved effective in
migraine patients with a reduction of frequency, inten-
sity and duration of the attacks. Adverse effects were
intense headache with doses above 10 ng and 4 ng in
healthy volunteers and migraine patients respectively.
The authors attributed this to an increased H1 agonistic
effect [60]. A double blind placebo controlled phase III
study was performed and results were published in 2006.
Sixty patients with migraine (50 migraine without aura
and 10 migraine with aura) were included. Two from the
placebo group and 3 patients from the Nα group left the
study and 55 patients completed the 12 week period.
The study confirmed the results seen in the phase II trial
Fig. 3 Downstream signaling from the H3 receptor. Opposite to the
H2 receptor, adenylate cyclase is inhibited by the H3 receptor.
Reprinted from (13) Copyright© 2016 with permission from ASPET,
Mol Pharmacol
Fig. 4 Structural formula of pitolisant
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along with lower intake of rescue analgesics in the
Nα-group vs. the placebo group and without any adverse
events. The hypothesis in the study was that low doses
of a H3 agonist modulates the interaction between mast
cells and C-fiber endings and by reducing histamine
release lowering the neurogenic inflammation [61]. The
doses used in these studies are unusually low making it
difficult to understand the mechanism of action or to
even accept the results of such minute doses. Further-
more, Nα-methylhistamine does not cross the blood
brain barrier. Apparently, no filing for registration of
Nα-methylhistamine has been done, so industry is not
convinced of these results.
The only H3 receptor agent approved for medical use
is pitolisant, an H3 inverse agonist. Pitolisant has re-
cently been discovered to be an efficient treatment of
narcolepsy and marketed by Bioprojet Pharma as Wakix.
The mechanism behind is increased histamine in the
brain leading to an increased wakefulness. One of the
pivotal studies described headache as an adverse event
in 35% of the participants [62]. In a review by Schwartz
of the first clinical trials with pitolisant in narcolepsy
and Parkinson’s disease, he also describes headache as
an adverse event of pitolisant. Overall in these studies
9.7% developed headache on pitolisant compared to
2.9% on placebo [63]. Pitolisant readily crosses the blood
brain barrier [3] but histamine is known to lack this
ability. It remains unclear if this headache observed
in the pitolisant trials is due to central or peripheral
mechanisms but it is interesting that a drug which
promotes histamine release is linked to an increased
susceptibility of headache.
The discovery of the histamine H4 receptor was
reported by several independent research groups around
the turn of the millennium. The H4 receptor has ~ 40%
homology with the H3 receptor. Two additional inactive
isoforms have been identified [3]. The H4 receptor is a
coupled to Gi/Go protein and uses intracellular Ca
2+ as
the primary second messenger. In recombinant systems
cAMP increase or decrease has been coupled to an
agonist response and inverse agonist response, res-
pectively, indicating mediation by adenylate cyclase. There
are probably additional signaling mechanisms and sup-
porting evidence is emerging. The localization of the H4
receptor is complicated by deficiency of validated H4
selective antibodies to identify the H4 receptor expression.
Consensus is that H4 receptors are present in the bone
marrow and hematopoietic cells. H4 receptor expression
was also shown in sensory neurons innervating skin in
mice but there is no evidence for its presence in human
sensory neurons yet. Pharmacological methods have
shown that the H4 receptor is expressed on mast cells [3]
and there is some evidence that microglial cells express
H4 receptors [64].
The literature describes an immune modulating func-
tion of the H4 receptor with an involvement in inflamma-
tory responses. It mediates chemotaxis and is involved in
cytokine release from various immune cells. Coruzzi et al.
suggested anti-inflammatory and antinociceptive effects of
H4 antagonists in a rat model [65], a characteristic shared
with the H3 receptor [3]. The H4 receptor has not yet been
associated with migraine and further description of its
localization and function is needed.
Conclusions and future perspectives
Histamine receptors H1, H2, H3 and H4 are widespread
throughout the body but there is limited knowledge about
the H4 receptor. H3 is an autoreceptor, inhibiting release
of histamine where H1 and H2 have pure agonistic effects
and have effect on multiple sites. Modern provocation
studies with histamine have increased the interest in the
histaminergic system in relation to migraine because
histamine proved to be an effective migraine provoking
agent. Studies of the effect of antihistamines in migraine
are limited and of poor quality. Thus, there is little sup-
port for H1 or H2 antihistamines as preventive migraine
medication. In addition, there are undesirable adverse
effects. Still, non-sedating H1 antihistamines need to be
appropriately tested. This has not been done and it might
provide valuable information of histamine’s site of action
and it’s relation to migraine. There are positive reports
about the H3 receptor agonist N
α-methylhistamine as
migraine treatment, but the use of almost homeopathic
doses makes the results less credible. Additional explo-
ration of the histaminergic system, peripheral and central,
could reveal further goals for migraine therapy.
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